Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Rebif

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Rebif was produced by Merck KGaA.

Merck sees €2bn from new launches by 2022

Merck sees €2bn from new launches by 2022 s existing MS expertise with interferon beta product Rebif.

Fertility drugs drive healthcare growth at Merck KGaA

Fertility drugs drive healthcare growth at Merck KGaA Strong performances from Gonal-f and Rebif boost the firm’s 2016 sales forecast. ... Merck makes the most of its portfolio of mature drugs, and top-seller Rebif (interferon beta-1a) for relapsing-remitting multiple sclerosis held up fairly well despite

Roche's MS drug Ocrevus awarded priority review by FDA

Roche's MS drug Ocrevus awarded priority review by FDA Ocrevus is the first investigational medicine with the potential to treat both forms, outperforming Merck's Rebif in phase II trials. ... In the Opera I and II clinical trials for RMS, Ocrevus reduced annual relapse rates and the progression of clinical

Merck licences MS brain training programme

Merck licences MS brain training programme Strikes deal with HAPPYneuron to bolster its MSdialog platform for Rebif. ... HAPPYneuron will be added to Merck's MSdialog, a cloud-based software system that records patient outcome data and provides patients prescribed the firm's Rebif (interferon beta

Roche planning ocrelizumab filings in early 2016

Roche planning ocrelizumab filings in early 2016 Firm claims MS candidate outperformed Merck Serono’s Rebif in two phase III trials. ... In the latest studies – called OPERA I and OPERA II – side effects were comparable to Rebif and there was no increase in serious infections with ocrelizumab.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...